Clinicians' preferences for managing aneurysmal subarachnoid hemorrhage using endothelin receptor antagonists

BACKGROUND: The endothelin receptor antagonist (ERA) clazosentan is being investigated for the medical prevention of cerebral vasospasm and associated complications, such as delayed cerebral ischemia (DCI), after aneurysmal subarachnoid hemorrhage (aSAH). This study quantified how clinicians weigh t...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidenreich, Sebastian, Trapali, Myrto, Krucien, Nicolas, Phillips-Beyer, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017541/
https://www.ncbi.nlm.nih.gov/pubmed/36937515
http://dx.doi.org/10.3389/fneur.2023.1102290

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10017541/
https://www.ncbi.nlm.nih.gov/pubmed/36937515
http://dx.doi.org/10.3389/fneur.2023.1102290

Ejemplares similares